JP2021522276A5 - - Google Patents
Info
- Publication number
- JP2021522276A5 JP2021522276A5 JP2020560316A JP2020560316A JP2021522276A5 JP 2021522276 A5 JP2021522276 A5 JP 2021522276A5 JP 2020560316 A JP2020560316 A JP 2020560316A JP 2020560316 A JP2020560316 A JP 2020560316A JP 2021522276 A5 JP2021522276 A5 JP 2021522276A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound according
- membered
- pharmaceutically acceptable
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024004034A JP7838004B2 (ja) | 2018-04-30 | 2024-01-15 | Ｐｏｌｙｂｒｏｍｏ－１（ｐｂｒｍ１）の小分子分解剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862664592P | 2018-04-30 | 2018-04-30 | |
| US62/664,592 | 2018-04-30 | ||
| PCT/US2019/029778 WO2019213005A1 (en) | 2018-04-30 | 2019-04-30 | Small molecule degraders of polybromo-1 (pbrm1) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024004034A Division JP7838004B2 (ja) | 2018-04-30 | 2024-01-15 | Ｐｏｌｙｂｒｏｍｏ－１（ｐｂｒｍ１）の小分子分解剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021522276A JP2021522276A (ja) | 2021-08-30 |
| JP2021522276A5 true JP2021522276A5 (enExample) | 2022-05-09 |
| JP7471232B2 JP7471232B2 (ja) | 2024-04-19 |
Family
ID=68386081
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560316A Active JP7471232B2 (ja) | 2018-04-30 | 2019-04-30 | Ｐｏｌｙｂｒｏｍｏ－１（ｐｂｒｍ１）の小分子分解剤 |
| JP2024004034A Active JP7838004B2 (ja) | 2018-04-30 | 2024-01-15 | Ｐｏｌｙｂｒｏｍｏ－１（ｐｂｒｍ１）の小分子分解剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024004034A Active JP7838004B2 (ja) | 2018-04-30 | 2024-01-15 | Ｐｏｌｙｂｒｏｍｏ－１（ｐｂｒｍ１）の小分子分解剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11771697B2 (enExample) |
| EP (1) | EP3787747A4 (enExample) |
| JP (2) | JP7471232B2 (enExample) |
| AU (1) | AU2019261938B2 (enExample) |
| CA (1) | CA3093405C (enExample) |
| WO (1) | WO2019213005A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| CN111372585A (zh) | 2017-11-16 | 2020-07-03 | C4医药公司 | 用于靶蛋白降解的降解剂和降解决定子 |
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| EP3773576A4 (en) | 2018-03-26 | 2021-12-29 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| EP3781156A4 (en) | 2018-04-16 | 2022-05-18 | C4 Therapeutics, Inc. | SPIROCYCLIC COMPOUNDS |
| EP3784665A4 (en) * | 2018-04-26 | 2022-01-26 | Aurigene Discovery Technologies Limited | PYRIDAZINE DERIVATIVES AS SMARCA2/4 DEGRADERS |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| AU2019348094B2 (en) * | 2018-09-30 | 2022-12-22 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Isoindoline compound, preparation method, pharmaceutical composition and use thereof |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| JP2023511471A (ja) * | 2019-10-28 | 2023-03-20 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 二官能性化合物 |
| JP2023511472A (ja) * | 2019-10-29 | 2023-03-20 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療のための二官能性化合物 |
| EP4081308A4 (en) | 2019-12-23 | 2024-01-24 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| WO2021133917A1 (en) | 2019-12-23 | 2021-07-01 | Kymera Therapeutics, Inc. | Smarca inhibitors and uses thereof |
| WO2021142247A1 (en) * | 2020-01-10 | 2021-07-15 | Amgen Inc. | Smarca2-vhl degraders |
| US20240000950A1 (en) * | 2020-08-07 | 2024-01-04 | Cornell University | Therapeutic cure-pro compounds for targeted degradation of bet domain proteins, and methods of making and using them |
| WO2022099117A1 (en) * | 2020-11-06 | 2022-05-12 | Prelude Therapeutics Incorporated | Brm targeting compounds and associated methods of use |
| JP7600396B2 (ja) * | 2020-11-20 | 2024-12-16 | フォグホーン セラピューティクス インコーポレイテッド | 化合物及びその使用 |
| JP7723743B2 (ja) * | 2020-11-20 | 2025-08-14 | フォグホーン セラピューティクス インコーポレイテッド | 化合物及びその使用 |
| EP4259144A4 (en) | 2020-12-09 | 2025-08-20 | Kymera Therapeutics Inc | SMARCA DEGRADING AGENTS AND THEIR USES |
| AU2022270089A1 (en) * | 2021-05-03 | 2023-11-16 | Nurix Therapeutics, Inc. | Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use |
| KR20240046498A (ko) | 2021-08-09 | 2024-04-09 | 제넨테크, 인크. | Brm의 조절에 사용하기 위한 페놀 유도체 |
| CA3249074A1 (en) | 2022-06-06 | 2023-12-14 | C4 Therapeutics, Inc. | BICYCLIC SUBSTITUTION GLUTARIMIDE CEREBLON BINDERS |
| PE20260307A1 (es) | 2023-06-14 | 2026-02-11 | Astrazeneca Ab | Degradadores de smarca2 y usos de estos |
| PE20260301A1 (es) | 2023-06-14 | 2026-02-10 | Astrazeneca Ab | Derivados de 3-[3-amino-6-(2-hidroxifenil)piridazin-4-il]-3,8-diazabiciclo[3.2.1]octano como protacs degradantes de smarca2 para el tratamiento del cancer |
| WO2025106472A1 (en) * | 2023-11-13 | 2025-05-22 | Regents Of The University Of Michigan | Compounds and compositions as smarca2/4 degraders and uses thereof |
| WO2026061475A1 (zh) * | 2024-09-19 | 2026-03-26 | 标新生物医药科技(上海)有限公司 | 含有芳基取代杂芳基的双功能蛋白降解剂及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| MA41598A (fr) * | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| SG11201808728QA (en) * | 2016-04-06 | 2018-11-29 | Univ Michigan Regents | Mdm2 protein degraders |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CA3036841A1 (en) | 2016-09-13 | 2018-03-22 | The Regents Of The University Of Michigan | Fused 1,4-diazepines as bet protein degraders |
| WO2019023149A1 (en) * | 2017-07-24 | 2019-01-31 | Salk Institute For Biological Studies | USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES |
| US20190300521A1 (en) * | 2018-04-01 | 2019-10-03 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
| EP3784665A4 (en) * | 2018-04-26 | 2022-01-26 | Aurigene Discovery Technologies Limited | PYRIDAZINE DERIVATIVES AS SMARCA2/4 DEGRADERS |
-
2019
- 2019-04-30 US US17/042,634 patent/US11771697B2/en active Active
- 2019-04-30 JP JP2020560316A patent/JP7471232B2/ja active Active
- 2019-04-30 WO PCT/US2019/029778 patent/WO2019213005A1/en not_active Ceased
- 2019-04-30 AU AU2019261938A patent/AU2019261938B2/en active Active
- 2019-04-30 EP EP19797003.1A patent/EP3787747A4/en active Pending
- 2019-04-30 CA CA3093405A patent/CA3093405C/en active Active
-
2024
- 2024-01-15 JP JP2024004034A patent/JP7838004B2/ja active Active